Interestingly, it was reported that DMF treatment resulted in a preferential loss of CD8+ T cells compared with CD4+ T cells in patients with MS (42–46), while the proportions of Treg cells, circulating CD56(hi) NK cells, monocytes, and DCs were unaffected (43, 47). Here, CD8A is linked to myeloid sarcoma.